Mark A. Levstik, M.B.B.Ch., B.A.O.

Dr. Levstik leads the Hepatology and Liver Transplant Program at University of Rochester Medical Center. He is actively involved in the Live Donor Liver Program and the evaluation and treatment of chronic liver disease. His research interests involve liver transplant quality, live donor liver transplantation and non-invasive Liver Fibrosis Measurement (FibroScan). He is a member of the European and Canadian Associations for the Study of the Liver and has presented nationally and internationally.

Credentials

Specialties

Gastroenterology
Internal Medicine

Education

1985
BSc | Canada-U Western Ontario, London
Biology

1990
MB BCh | Ireland-Royal Coll Surgeons
Medicine

1990
BAO | Ireland-Royal Coll Surgeons
Obstetrics

Post-doctoral Training & Residency

08/01/1996 - 07/01/1997
Fellowship in Transplant Hepatology at University of Western Ontario

07/01/1994 - 07/30/1996
Fellowship in Gastroenterology at University of Iowa College of Medicine

07/01/1993 - 06/30/1994
Residency in Internal Medicine at Blodgett Memorial Medical Center

07/01/1992 - 06/30/1993
Residency in Internal Medicine at Blodgett Memorial Medical Center

07/01/1990 - 06/30/1992
Internship in Internal Medicine at Blodgett Memorial Medical Center

VIEW ALL

Awards

1997 - 1998
University of Toronto Teaching Award
Sponsor: University of Toronto Hospitals, Western Division
Location: Toronto, ON, Canada M5T 2S8

Publications

Journal Articles

12/1/2018
"Can we reduce ischemic cholangiopathy rates in donation after cardiac death liver transplantation after 10 years of practice? Canadian single-centre experience" Canadian journal of surgery. Journal canadien de chirurgie.. 2018 Dec 1; 62(1):8. Epub 2018 Dec 01.

2014
Lingard L,; Mcdougall A,; Levstik MA,; Schryer C. "Using Loose Coupling to Understand Interprofessional Collaborative Practice on a Transplantation Team". DOI. 2014; 3(3): 112.

2013
Beaton MD; Chakrabarti S; Levstik MA; Speechley M; Marotta P; Adams PC. "Phase II Clinical Trial of Phlebotomy for Non-Alcoholic Fatty Liver Disease". Alimentary Pharmacology & Therapeutics. 2013; 37(7): 720-9.

VIEW ALL PUBLICATIONS